Navigation Links
UCSF unveils model for implantable artificial kidney to replace dialysis
Date:9/2/2010

rtension.

Yet transplants are difficult to obtain: a mere 17,000 donated kidneys were available for transplant last year, while the number of patients on the transplant waiting list currently exceeds 85,000, according to the Organ Procurement ant Transplant Network.

Roughly 350,000 patients are reliant on kidney dialysis, Roy explained, which comes at a tremendous cost. The Medicare system alone spends $25 billion on treatments for kidney failure more than 6 percent of the total budget while the disease affects only 1 percent of Medicare recipients, he said. That cost includes almost $75,000 per patient each year for dialysis, according to the U.S. Renal Data System.

Dialysis also takes a human toll. A typical dialysis schedule is three sessions per week, for 3 to 5 hours per session, in which blood is pumped through an external circuit for filtration. This is exhausting for patients and only replaces 13 percent of kidney function, Roy said. As a result, only 35 percent of patients survive for more than 5 years.

With the limited supply of donors, that means thousands of patients die each year waiting for a kidney.

The implantable device aims to eradicate that problem. The two-stage system uses a hemofilter to remove toxins from the blood, while applying recent advances in tissue engineering to grow renal tubule cells to provide other biological functions of a healthy kidney. The process relies on the body's blood pressure to perform filtration without needing pumps or an electrical power supply.

The project exemplifies the many efforts under way at UCSF to build collaborations across scientific disciplines that accelerate the translation of academic research into real solutions for patients, according to Mary Anne Koda-Kimble, PharmD, dean of the UCSF School of Pharmacy.

"This is a perfect example of the work we are doing at UCSF to address some of the most critical medical issues of our time, both
'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. NPL unveils quantitative means of monitoring ultrasonic cleaning systems
2. McMaster study unveils lifeline for antibiotic of last resort
3. GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits
4. MSU researcher unveils new approach to treat lower back pain
5. GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits
6. HAMILTON Unveils ARC Sensor Technology
7. Largest ever Alzheimers genome study unveils dementia mysteries
8. Uniloc Unveils Industry-First Authentication Technology for Comprehensive Protection of Critical Infrastructure
9. Uniloc Unveils Industry-First Authentication Technology for Comprehensive Protection of Critical Infrastructure
10. NPL unveils new equipment to make cancer treatment safer
11. Promptu Unveils High Accuracy Voice-to-Text Dictation for Mobile Phones at CTIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... MADISON People get type 2 diabetes. So do cats. ... in the shape of proteins protect some and endanger others. ... it only differs a little bit from species to species," ... mammals that get type 2 diabetes, their amylin proteins aggregate ...
... Energy is making good on the second phase of a plant ... by Dr. Joshua Yuan, Texas A&M AgriLife Research plant pathologist., ... Yuan, who was granted $1.8 million for Phase I by the ... source., The scientist said his research is moving ahead so quickly ...
... the Earth has reached the limits of its biophysical ... and social norms relating to material production and consumption ... functioning of our planet,s life support systems. ... pivotal role to play in this transition. This timely ...
Cached Biology News:New look identifies crucial clumping of diabetes-causing proteins 2Plant fuel project moves to second phase under US Energy Department grant 2
(Date:5/28/2015)... DryLet, LLC a biotechnology company providing ... animal waste reduction, bioremediation, wastewater treatment, aquaculture and ... plants and restaurant kitchen settings, announced today it ... 3-5 in Des Moines, Iowa. , ManureMagicâ„¢ was ... Journal article because of its industry-leading qualities and ...
(Date:5/28/2015)... 2015  PDS Biotechnology Corp. announces preliminary data ... HPV-16, has generated strong T-cell responses in pre-cervical ... is treated by surgical removal of lesions however, ... alternative. Results show that it primes and activates ... and kill precancerous and cancerous cells that display ...
(Date:5/28/2015)... Fla. , May 28, 2015 ... the anti-cancer potential of its growth hormone-releasing hormone (GHRH) ... at the 2015 ASCO Annual Meeting. The data show ... for Biscayne,s anti-cancer GHRH blockers, is present on many ... These findings suggest that GHRH antagonists could have broad ...
(Date:5/28/2015)... May 28, 2015 CD-adapco, the ... Engineering software, announced today it is joining the ... will provide state-of-the-art engineering simulation tools for analyzing ... expertise and experiences in analyzing particle flow that ... and advance the understanding of flow modeling solutions. ...
Breaking Biology Technology:DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... ... , ... October 19, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical ... Medicine, Academy of Sciences of the Czech Republic, to study the effects of air ...
... Inc., today announced that the U.S. Food and Drug ... for the first 15 monoclonal antibodies in its proprietary ... use by blood donor centers, reference laboratories, and hospitals ... was formed earlier this year to directly commercialize its ...
... 17 UCB today announced data that showed rapid ... fatigue of rheumatoid arthritis (RA) as early as the ... damage (seen at week 24) following treatment with Cimzia® ... to 100 weeks. Cimzia® is approved for the treatment ...
Cached Biology Technology:Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 2Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 3Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 4Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance To Enter U.S. Transfusion Diagnostics Market 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12
...
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... to HDAC8 Regulation of gene ... such as DNA methylation, ATP-dependent chromatin ... histones, which include the dynamic acetylation ... lysine residues present in the tail ...
... Membrane Proteins ,Contains sufficient components to ... 2-D gel analysis , ,Includes:, , ... , (contains sufficient reagents for extracting ... weight of 10 mg each) Kit ...
Biology Products: